Additives boosting the performance of tungsten imido-mediated ethylene dimerization systems for industrial application.

While activation of tungsten bis(imido) complexes [WCl2(NAr)2(dme)] with EtAlCl2 affords active, and moderately selective ethylene dimerization catalysts, addition of Et3N or Oct4NCl leads to a doubling in productivity and activity, along with increased selectivity (e.g., >93% C4, >99% 1-C4). The performance of the resulting tungsten-based catalyst package is competitive with that of Axens' commercialised Ti-based AlphaButol process and exemplifies the wide potential of similar additives in selective oligomerization.

Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis.

OBJECTIVES: Treating infections of Gram-negative pathogens, in particular Pseudomonas aeruginosa, is a challenge for clinicians in the Asia-Pacific region owing to inherent and acquired antimicrobial resistance. This systematic review and meta-analysis provides updated information on risk factors for P. aeruginosa infection in Asia-Pacific as well as the consequences (e.g. mortality, costs) of initial inappropriate antimicrobial therapy (IIAT). METHODS: Embase and MEDLINE databases were searched for Asia-Pacific studies reporting the consequences of IIAT versus initial appropriate antimicrobial therapy (IAAT) in Gram-negative bacterial infections as well as risk factors for serious P. aeruginosa infection. A meta-analysis of unadjusted mortality was performed using a random-effects model. RESULTS: A total of 22 studies reporting mortality and 13 reporting risk factors were identified. The meta-analysis demonstrated that mortality was significantly lower in patients receiving IAAT versus IIAT, with a 67% reduction observed for 28- or 30-day all-cause mortality (odds ratio=0.33, 95% confidence interval 0.20-0.55; P<0.001). Risk factors for serious P. aeruginosa infection include previous exposure to antimicrobials, mechanical ventilation and previous hospitalisation. CONCLUSION: High rates of antimicrobial resistance in Asia-Pacific as well as the increased mortality associated with IIAT and the presence of risk factors for serious infection highlight the importance of access to newer and appropriate antimicrobials.

Differential role of pannexin-1/ATP/P2X7 axis in IL-1ß release by human monocytes.

IL-1ß release is integral to the innate immune system. The release of mature IL-1ß depends on 2 regulated events: the de novo induction of pro-IL-1ß, generally via NF-κB-dependent transduction pathways; and the assembly and activation of the NLRP3 inflammasome. This latter step is reliant on active caspase-1, pannexin-1, and P2X7 receptor activation. Pathogen-associated molecular patterns in gram-positive and gram-negative bacteria activate IL-1ß release from immune cells via TLR2 and TLR4 receptors, respectively. We found that pro-IL-1ß and mature IL-1ß release from human monocytes is stimulated by the TLR2 agonists Pam3CSK4 or FSL-1, as well as the TLR4 agonist LPS in the absence of additional ATP. TLR2 agonists required pannexin-1 and P2X7 receptor activation to stimulate IL-1ß release. In contrast, IL-1ß release stimulated by the TLR4 agonist LPS is independent of both pannexin-1 and P2X7 activation. In the absence of exogenous ATP, P2X7 activation requires endogenous ATP release, which occurs in some cells via pannexin-1. In line with this, we found that LPS-stimulated human monocytes released relatively low levels of ATP, whereas cells stimulated with TLR2 agonists released high levels of ATP. These findings suggest that in human monocytes, both TLR2 and TLR4 signaling induce pro-IL-1ß expression, but the mechanism by which they activate caspase-1 diverges at the level of the pannexin-1/ATP/P2X7 axis.-Parzych, K., Zetterqvist, A. V., Wright, W. R., Kirkby, N. S., Mitchell, J. A., Paul-Clark, M. J. Differential role of pannexin-1/ATP/P2X7 axis in IL-1ß release by human monocytes.

COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks.

Cyxlo-oxygenase (COX)-2 inhibitors, including traditional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with increased cardiovascular side effects, including myocardial infarction. We and others have shown that COX-1 and not COX-2 drives vascular prostacyclin in the healthy cardiovascular system, re-opening the question of how COX-2 might regulate cardiovascular health. In diseased, atherosclerotic vessels, the relative contribution of COX-2 to prostacyclin formation is not clear. Here we have used apoE(-/-)/COX-2(-/-) mice to show that, whilst COX-2 profoundly limits atherosclerosis, this protection is independent of local prostacyclin release. These data further illustrate the need to look for new explanations, targets and pathways to define the COX/NSAID/cardiovascular risk axis. Gene expression profiles in tissues from apoE(-/-)/COX-2(-/-) mice showed increased lymphocyte pathways that were validated by showing increased T-lymphocytes in plaques and elevated plasma Th1-type cytokines. In addition, we identified a novel target gene, rgl1, whose expression was strongly reduced by COX-2 deletion across all examined tissues. This study is the first to demonstrate that COX-2 protects vessels against atherosclerotic lesions independently of local vascular prostacyclin and uses systems biology approaches to identify new mechanisms relevant to development of next generation NSAIDs.

Role of prostacyclin in pulmonary hypertension.

Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it's discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension.

Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies.

Cyclooxygenase 2 (COX)-2 is induced by bacterial and viral infections and has complex, poorly understood roles in anti-pathogen immunity. Here, we use a knock-in luciferase reporter model to image Cox2 expression across a range of tissues in mice following treatment with the either the prototypical bacterial pathogen-associated molecular pattern (PAMP), LPS, which activates Toll-like receptor (TLR)4, or with poly(I:C), a viral PAMP, which activates TLR3. LPS induced Cox2 expression in all tissues examined. In contrast, poly(I:C) elicited a milder response, limited to a subset of tissues. A panel of cytokines and interferons was measured in plasma of wild-type, Cox1(-/-) and Cox2(-/-) mice treated with LPS, poly(I:C), MALP2 (TLR2/6), Pam3CSK4 (TLR2/1), R-848 (TLR7/8) or CpG ODN (TLR9), to establish whether/how each COX isoform modulates specific PAMP/TLR responses. Only LPS induced notable loss of condition in mice (inactivity, hunching, piloerection). However, all TLR agonists produced cytokine responses, many of which were modulated in specific fashions by Cox1 or Cox2 gene deletion. Notably we observed opposing effects of Cox2 gene deletion on the responses to the bacterial PAMP, LPS, and the viral PAMP, poly(I:C), consistent with the differing abilities of the PAMPs to induce Cox2 expression. Cox2 gene deletion limited the plasma IL-1ß and interferon-γ responses and hypothermia produced by LPS. In contrast, in response to poly(I:C), Cox2(-/-) mice exhibited enhanced plasma interferon (IFNα,ß,γ,λ) and related cytokine responses (IP-10, IL-12). These observations suggest that a COX-2 selective inhibitor, given early in infection, may enhance and/or prolong endogenous interferon responses, and thereby increase anti-viral immunity.

Cyclooxygenase and cytokine regulation in lung fibroblasts activated with viral versus bacterial pathogen associated molecular patterns.

Cyclooxygenase (COX) is required for prostanoid (e.g. prostaglandin PGE2) production. Constitutive COX-1 and inducible COX-2 are implicated in lung diseases, such as idiopathic pulmonary fibrosis (IPF). Using lung fibroblasts from humans and wild type, COX-1(-/-) and COX-2(-/-) mice, we investigated how COX activity modulates cell growth and inflammatory responses induced by activators of Toll-like receptors (TLRs) 1-8. In mouse tissue, PGE2 release from fresh lung was COX-1 driven, in lung in culture (24h) COX-1 and COX-2 driven, and from proliferating lung fibroblasts exclusively COX-2 driven. COX-2 limited proliferation in lung fibroblasts and both isoforms limited KC release induced by a range of TLR agonists. Less effect of COX was seen on TLR-induced IP-10 release. In human lung fibroblasts inhibition of COX with diclofenac was associated with increased release of IL-8 and IP-10. Our results may have implications for the treatment of IPF.

Development of heterogeneous catalysts for the conversion of levulinic acid to γ-valerolactone.

γ-Valerolactone (GVL) has been identified as a potential intermediate for the production of fuels and chemicals based on renewable feedstocks. Numerous heterogeneous catalysts have been used for GVL production, alongside a range of reaction setups. This Minireview seeks to outline the development of heterogeneous catalysts for the targeted conversion of levulinic acid (LA) to GVL. Emphasis has been placed on discussing specific systems, including heterogeneous noble and base metal catalysts, transfer hydrogenation, and application of scCO2 as reaction medium, with the aim of critically highlighting both the achievements and remaining challenges associated with this field.

Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke.

BACKGROUND: Cigarette smoking is responsible for 5 million deaths worldwide each year, and is a major risk factor for cardiovascular and lung diseases. Cigarette smoke contains a complex mixture of over 4000 chemicals containing 10(15) free radicals. Studies show smoke is perceived by cells as an inflammatory and xenobiotic stimulus, which activates an immune response. The specific cellular mechanisms driving cigarette smoke-induced inflammation and disease are not fully understood, although the innate immune system is involved in the pathology of smoking related diseases. METHODOLOGY/PRINCIPLE FINDINGS: To address the impact of smoke as an inflammagen on the innate immune system, THP-1 cells and Human PBMCs were stimulated with 3 and 10% (v/v) cigarette smoke extract (CSE) for 8 and 24 hours. Total RNA was extracted and the transcriptome analysed using Illumina BeadChip arrays. In THP-1 cells, 10% CSE resulted in 80 genes being upregulated and 37 downregulated by ≥1.5 fold after 8 hours. In PBMCs stimulated with 10% CSE for 8 hours, 199 genes were upregulated and 206 genes downregulated by ≥1.5 fold. After 24 hours, the number of genes activated and repressed by ≥1.5 fold had risen to 311 and 306 respectively. The major pathways that were altered are associated with cell survival, such as inducible antioxidants, protein chaperone and folding proteins, and the ubiquitin/proteosome pathway. CONCLUSIONS: Our results suggest that cigarette smoke causes inflammation and has detrimental effects on the metabolism and function of innate immune cells. In addition, THP-1 cells provide a genetically stable alternative to primary cells for the study of the effects of cigarette smoke on human monocytes.

Application of molybdenum bis(imido) complexes in ethylene dimerisation catalysis.

In combination with EtAlCl(2) (Mo : Al = 1 : 15) the imido complexes [MoCl(2)(NR)(NR')(dme)] (R = R' = 2,6-Pr(i)(2)-C(6)H(3) (1); R = 2,6-Pr(i)(2)-C(6)H(3), R' = Bu(t) (3); R = R' = Bu(t) (4); dme = 1,2-dimethoxyethane) and [Mo(NHBu(t))(2)(NR)(2)] (R = 2,6-Pr(i)(2)-C(6)H(3) (5); R = Bu(t) (6)) each show moderate TON, activity, and selectivity for the catalytic dimerisation of ethylene, which is influenced by the nature of the imido substituents. In contrast, the productivity of [MoCl(2)(NPh)(2)(dme)] (2) is low and polymerisation is favoured over dimerisation. Catalysis initiated by complexes 1-4 in combination with MeAlCl(2) (Mo : Al = 1 : 15) exhibits a significantly lower productivity. Reaction of complex 5 with EtAlCl(2) (2 equiv.) gives rise to a mixture of products, while addition of MeAlCl(2) affords [MoMe(2)(N-2,6-Pr(i)(2)-C(6)H(3))(2)]. Treatment of 6 with RAlCl(2) (2 equiv.) (R = Me, Et) yields [Mo({µ-N-Bu(t)}AlCl(2))(2)] (7) in both cases. Imido derivatives 1 and 3 react with Me(3)Al and MeAlCl(2) to form the bimetallic complexes [MoMe(2)(N{R}AlMe(2){µ-Cl})(NR')] (R = R' = 2,6-Pr(i)(2)-C(6)H(3) (8); R = 2,6-Pr(i)(2)-C(6)H(3), R' = Bu(t) (10)) and [MoMe(2)(N{R}AlCl(2){µ-Cl})(NR')] (R = R' = 2,6-Pr(i)(2)-C(6)H(3) (9); R = 2,6-Pr(i)(2)-C(6)H(3), R' = Bu(t) (11)), respectively. Exposure of complex 8 to five equivalents of thf or PMe(3) affords the adducts [MoMe(2)(N-2,6-Pr(i)(2)-C(6)H(3))(2)(L)] (L = thf (12); L = PMe(3) (13)), while reaction with NEt(3) (5 equiv.) yields [MoMe(2)(N-2,6-Pr(i)(2)-C(6)H(3))(2)]. The molecular structures of complexes 5, 9 and 11 have been determined.

Transition metal catalysed ammonia-borane dehydrogenation in ionic liquids.

Significant advantages result from combining the disparate hydrogen release pathways for ammonia-borane (AB) dehydrogenation using ionic liquids (ILs) and transition metal catalysts. With the RuCl(2)(PMe(3))(4) catalyst precursor, AB dehydrogenation selectivity and extent are maximized in an IL with a moderately coordinating ethylsulfate anion.

Exploring the reactivity of tungsten bis(imido) dimethyl complexes with methyl aluminium reagents: implications for ethylene dimerization.

The reaction of [WCl2(NAr)2(DME)] (1) with excess Me3Al affords the dimethyl complex [WMe2(N{Ar}AlMe2{mu-Cl})(NAr)] (2), which on treatment with THF or MeAlCl2 yields [WMe2(NAr)2(THF)] (3) and [WMe2(N{Ar}AlMe(Cl){mu-Cl})(NAr)] (5), respectively. Complex 3 is unstable in solution dissociating to form [WMe2(NAr)2] (4) that may be isolated as an adduct with PMe3, [WMe2(NAr)2(PMe3)] (6). While complex 2 is inert towards ethylene, complex 3 reacts rapidly to afford a mixture of methane and but-1-ene (1:4). Neither complex 2 nor 3 react with propylene. Reaction of 3 with a C2H4/C2D4 (1:1) affords a mixture of isotopomers that is consistent with complete isotopic scrambling. The structures of complexes 1, 2, and 3 have been determined by X-ray diffraction.